A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group.
D-VD
Lenalidomide refractoriness
Multiple myeloma
Real-life
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
20 Sep 2023
20 Sep 2023
Historique:
received:
04
08
2023
accepted:
05
09
2023
medline:
21
9
2023
pubmed:
21
9
2023
entrez:
21
9
2023
Statut:
aheadofprint
Résumé
Treatment of lenalidomide refractory (Len-R) multiple myeloma (MM) patients still represents an unmet clinical need. In the last years, daratumumab-bortezomib-dexamethasone (D-VD) combination was extensively used in this setting, even though only a small fraction of Len-R patients was included in the pivotal trial. This real-life study aimed to evaluate the efficacy and safety of the D-VD regimen in a cohort that exclusively enrolled Len exposed or refractory MM patients. The study cohort included 57 patients affected by relapsed/refractory MM. All patients were previously exposed to Len, with 77.2% being refractory. The overall response rate (ORR) was 79.6% with 43% of cases obtaining at least a very good partial response (VGPR). The D-VD regimen showed a favorable safety profile, with low frequency of grade 3-4 adverse events, except for thrombocytopenia observed in 21.4% of patients. With a median follow-up of 13 months, median progression-free survival (PFS) was 17 months. No significant PFS differences were observed according to age, ISS, LDH levels, type of relapse, and high-risk FISH. Len exposed patients displayed a PFS advantage as compared to Len refractory patients (29 vs 16 months, p = 0.2876). Similarly, patients treated after Len maintenance showed a better outcome as compared to patients who had received a full-dose Len treatment (23 vs 13 months, p = 0.1728). In conclusion, our real-world data on D-VD combination showed remarkable efficacy in Len-R patients, placing this regimen as one of the standards of care to be properly taken into account in this MM setting.
Identifiants
pubmed: 37731147
doi: 10.1007/s00277-023-05443-8
pii: 10.1007/s00277-023-05443-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Thorsteinsdottir S, Dickman PW, Landgren O, Blimark C, Hultcrantz M, Turesson I, Bjorkholm M, Kristinsson SY (2018) Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. Haematologica 103(9):e412–e415. https://doi.org/10.3324/haematol.2017.183475
doi: 10.3324/haematol.2017.183475
pubmed: 29567776
pmcid: 6119139
Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A, Investigators A (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372(2):142–152. https://doi.org/10.1056/NEJMoa1411321
doi: 10.1056/NEJMoa1411321
pubmed: 25482145
Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Rollig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P, Investigators E (2015) Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med 373(7):621–631. https://doi.org/10.1056/NEJMoa1505654
doi: 10.1056/NEJMoa1505654
pubmed: 26035255
Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O’Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P, Investigators P (2016) Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 375(14):1319–1331. https://doi.org/10.1056/NEJMoa1607751
doi: 10.1056/NEJMoa1607751
pubmed: 27705267
Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG, Group T-MS (2016) Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 374(17):1621–1634. https://doi.org/10.1056/NEJMoa1516282
doi: 10.1056/NEJMoa1516282
pubmed: 27119237
McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, Bringhen S, Musto P, Anderson KC, Caillot D, Gay F, Moreau P, Marit G, Jung SH, Yu Z, Winograd B, Knight RD, Palumbo A, Attal M (2017) Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. J Clin Oncol 35(29):3279–3289. https://doi.org/10.1200/JCO.2017.72.6679
doi: 10.1200/JCO.2017.72.6679
pubmed: 28742454
pmcid: 5652871
Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T, Team FT (2014) Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 371(10):906–917. https://doi.org/10.1056/NEJMoa1402551
doi: 10.1056/NEJMoa1402551
pubmed: 25184863
Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C, Committee EG (2017) Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv52–iv61. https://doi.org/10.1093/annonc/mdx096
doi: 10.1093/annonc/mdx096
pubmed: 28453614
Moreau P, Zamagni E, Mateos MV (2019) Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide. Blood Cancer J 9(4):38. https://doi.org/10.1038/s41408-019-0200-1
doi: 10.1038/s41408-019-0200-1
pubmed: 30894516
pmcid: 6426995
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P, Investigators C (2016) Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med 375(8):754–766. https://doi.org/10.1056/NEJMoa1606038
doi: 10.1056/NEJMoa1606038
pubmed: 27557302
Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P (2017) Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 18(10):1327–1337. https://doi.org/10.1016/S1470-2045(17)30578-8
doi: 10.1016/S1470-2045(17)30578-8
pubmed: 28843768
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O’Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M, investigators Ot (2019) Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol 20(6):781–794. https://doi.org/10.1016/S1470-2045(19)30152-4
doi: 10.1016/S1470-2045(19)30152-4
pubmed: 31097405
Mateos MV, Sonneveld P, Hungria V, Nooka AK, Estell JA, Barreto W, Corradini P, Min CK, Medvedova E, Weisel K, Chiu C, Schecter JM, Amin H, Qin X, Ukropec J, Kobos R, Spencer A (2020) Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clin Lymphoma Myeloma Leuk 20(8):509–518. https://doi.org/10.1016/j.clml.2019.09.623
doi: 10.1016/j.clml.2019.09.623
pubmed: 32482541
Moreau P, Joshua D, Chng WJ, Palumbo A, Goldschmidt H, Hajek R, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosinol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, Dimopoulos MA (2017) Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia 31(1):115–122. https://doi.org/10.1038/leu.2016.186
doi: 10.1038/leu.2016.186
pubmed: 27491641
Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahlten-Kumeli A, Usmani SZ (2020) Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet 396(10245):186–197. https://doi.org/10.1016/S0140-6736(20)30734-0
doi: 10.1016/S0140-6736(20)30734-0
pubmed: 32682484
Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Spicka I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Mace S, Martin T, group Is (2021) Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet 397(10292):2361–2371. https://doi.org/10.1016/S0140-6736(21)00592-4
doi: 10.1016/S0140-6736(21)00592-4
pubmed: 34097854
Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Ahmadi T, Ukropec J, Kampfenkel T, Schecter JM, Qiu Y, Amin H, Vermeulen J, Carson R, Sonneveld P, Investigators AT (2021) Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol 22(6):801–812. https://doi.org/10.1016/S1470-2045(21)00128-5
doi: 10.1016/S1470-2045(21)00128-5
pubmed: 34087126
Rocchi S, Tacchetti P, Pantani L, Mancuso K, Rizzello I, di Giovanni BC, Scalese M, Dozza L, Marzocchi G, Martello M, Barila G, Antonioli E, Staderini M, Buda G, Petrini M, Cea M, Quaresima M, Furlan A, Bonalumi A, Cavo M, Zamagni E (2021) A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma. Hematol Oncol 39(1):41–50. https://doi.org/10.1002/hon.2820
doi: 10.1002/hon.2820
pubmed: 33085797
Martino EA, Conticello C, Zamagni E, Pavone V, Palmieri S, Musso M, Tacchetti P, Mele A, Catalano L, Vigna E, Bruzzese A, Mendicino F, Botta C, Vincelli ID, Farina G, Barone M, Cangialosi C, Mancuso K, Rizziello I, Rocchi S, Falcone AP, Mele G, Reddiconto G, Garibaldi B, Iaccino E, Tripepi G, Gamberi B, Di Raimondo F, Musto P, Neri A, Cavo M, Morabito F, Gentile M (2022) Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials. Hematol Oncol. https://doi.org/10.1002/hon.3035
doi: 10.1002/hon.3035
pubmed: 35638723
Morabito F, Zamagni E, Conticello C, Pavone V, Palmieri S, Bringhen S, Galli M, Mangiacavalli S, Derudas D, Rossi E, Ria R, Catalano L, Tacchetti P, Mele G, Donatella Vincelli I, Antonia Martino E, Vigna E, Botta C, Bruzzese A, Mele A, Pantani L, Rocchi S, Garibaldi B, Cascavilla N, Ballanti S, Tripepi G, Frigeri F, Pia Falcone A, Cangialosi C, Reddiconto G, Farina G, Barone M, Rizzello I, Musto P, De Stefano V, Musso M, Teresa Petrucci M, Offidani M, Neri A, Di Renzo N, Di Raimondo F, Boccadoro M, Cavo M, Gentile M (2022) Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. Eur J Haematol 108(3):178–189. https://doi.org/10.1111/ejh.13723
doi: 10.1111/ejh.13723
pubmed: 34716957
Bonello F, Rocchi S, Barila G, Sandrone M, Talarico M, Zamagni E, Scaldaferri M, Vedovato S, Bertiond C, Pavan L, Bringhen S, Cattel F, Zambello R, Cavo M, Mina R (2022) Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma. Front Oncol 12:851864. https://doi.org/10.3389/fonc.2022.851864
Bertamini L, Bertuglia G, Oliva S (2022) Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results. Front Oncol 12:844779. https://doi.org/10.3389/fonc.2022.844779
doi: 10.3389/fonc.2022.844779
pubmed: 35646628
pmcid: 9132127
Terpos E, Zambello R, Leleu X, Kuehr T, Badelita SN, Katodritou E, Brescianini A, Liang T, Wetten S, Caers J (2022) Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe. Cancers (Basel) 14(21):5311. https://doi.org/10.3390/cancers14215311
Mian H, Eisfeld C, Venner CP, Masih-Khan E, Kardjadj M, Jimenez-Zepeda VH, Khandanpour C, Lenz G, McCurdy A, Sebag M, Song K, LeBlanc R, White D, Stakiw J, Reiman A, Louzada M, Aslam M, Kotb R, Gul E, Reece D (2022) Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis. Front Oncol 12:826342. https://doi.org/10.3389/fonc.2022.826342
doi: 10.3389/fonc.2022.826342
pubmed: 35251992
pmcid: 8894582
Ho M, Zanwar S, Kapoor P, Gertz M, Lacy M, Dispenzieri A, Hayman S, Dingli D, Baudi F, Muchtar E, Leung N, Kourelis T, Warsame R, Fonder A, Hwa L, Hobbs M, Kyle R, Rajkumar SV, Kumar S (2021) The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). Blood Cancer J 11(9):158. https://doi.org/10.1038/s41408-021-00548-7
doi: 10.1038/s41408-021-00548-7
pubmed: 34552051
pmcid: 8458275
Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Gavriatopoulou M, Oriol A, Rabin N, Nooka A, Qi M, Beksac M, Jakubowiak A, Ding B, Zahlten-Kumeli A, Yusuf A, Dimopoulos M (2022) Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol 23(1):65–76. https://doi.org/10.1016/S1470-2045(21)00579-9
doi: 10.1016/S1470-2045(21)00579-9
pubmed: 34871550
Dimopoulos MA, Moreau P, Augustson B, Castro N, Pika T, Delimpasi S, De la Rubia J, Maiolino A, Reiman T, Martinez-Lopez J, Martin T, Mikhael J, Yong K, Risse ML, Asset G, Marion S, Hajek R (2022) Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis. Am J Hematol. https://doi.org/10.1002/ajh.26602
doi: 10.1002/ajh.26602
pubmed: 36565455
pmcid: 10084376
Botta C, Martino EA, Conticello C, Mendicino F, Vigna E, Romano A, Palumbo GA, Cerchione C, Martinelli G, Morabito F, Di Raimondo F, Gentile M (2021) Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens. Front Oncol 11:643490. https://doi.org/10.3389/fonc.2021.643490
doi: 10.3389/fonc.2021.643490
pubmed: 33937048
pmcid: 8079718